Roche’s Perjeta shows significant promise in phase 3 breast cancer trial

pharmanewsdaily- March 2, 2017 0

Roche has announced promising results from the APHINITY trial, a crucial Phase 3 study evaluating Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy. This ... Read More